Pfizer-BioNTech COVID-19 vaccine gains full U.S. regulatory approval
(Reuters) – The U.S. drug regulator on Monday granted full approval to the Pfizer Inc/BioNTech SE COVID–19 vaccine – the first to secure such Food and Drug Administration validation – prompting President Joe Biden to make a fresh pitch to vaccine skeptics to get the shot to fight the relentless pandemic. The FDA, which gave the two-dose vaccine emergency-use authorization in December, provided its full approval for use in people age 16
